Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. more
Time Frame | LAB | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.32% | -2.06% | -0.55% |
1-Month Return | 32.33% | -1.92% | 2.72% |
3-Month Return | -2.22% | -10.4% | 7.66% |
6-Month Return | -3.17% | -4.6% | 10.15% |
1-Year Return | 1.79% | 4.06% | 27.53% |
3-Year Return | -47.49% | 1.94% | 32.31% |
5-Year Return | -38.16% | 36.48% | 89.2% |
10-Year Return | -93.6% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 117.24M | 138.14M | 130.58M | 97.95M | 106.34M | [{"date":"2019-12-31","value":84.87,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.53,"profit":true},{"date":"2022-12-31","value":70.9,"profit":true},{"date":"2023-12-31","value":76.98,"profit":true}] |
Cost of Revenue | 52.96M | 54.82M | 53.31M | 60.90M | 55.89M | [{"date":"2019-12-31","value":86.97,"profit":true},{"date":"2020-12-31","value":90.02,"profit":true},{"date":"2021-12-31","value":87.55,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.78,"profit":true}] |
Gross Profit | 64.28M | 83.33M | 77.27M | 37.05M | 50.45M | [{"date":"2019-12-31","value":77.14,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":92.73,"profit":true},{"date":"2022-12-31","value":44.47,"profit":true},{"date":"2023-12-31","value":60.55,"profit":true}] |
Gross Margin | 54.83% | 60.32% | 59.17% | 37.83% | 47.44% | [{"date":"2019-12-31","value":90.89,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.1,"profit":true},{"date":"2022-12-31","value":62.71,"profit":true},{"date":"2023-12-31","value":78.65,"profit":true}] |
Operating Expenses | 116.12M | 134.36M | 144.72M | 153.26M | 113.49M | [{"date":"2019-12-31","value":75.77,"profit":true},{"date":"2020-12-31","value":87.67,"profit":true},{"date":"2021-12-31","value":94.43,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.05,"profit":true}] |
Operating Income | (51.84M) | (51.04M) | (67.46M) | (116.20M) | (76.60M) | [{"date":"2019-12-31","value":-5183900000,"profit":false},{"date":"2020-12-31","value":-5103600000,"profit":false},{"date":"2021-12-31","value":-6745900000,"profit":false},{"date":"2022-12-31","value":-11620500000,"profit":false},{"date":"2023-12-31","value":-7660000000,"profit":false}] |
Total Non-Operating Income/Expense | (19.14M) | (6.64M) | (24.00K) | (81.05M) | (2.26M) | [{"date":"2019-12-31","value":-1914500000,"profit":false},{"date":"2020-12-31","value":-663700000,"profit":false},{"date":"2021-12-31","value":-2400000,"profit":false},{"date":"2022-12-31","value":-8105400000,"profit":false},{"date":"2023-12-31","value":-226300000,"profit":false}] |
Pre-Tax Income | (66.70M) | (54.10M) | (63.66M) | (192.93M) | (74.20M) | [{"date":"2019-12-31","value":-6670500000,"profit":false},{"date":"2020-12-31","value":-5410100000,"profit":false},{"date":"2021-12-31","value":-6366000000,"profit":false},{"date":"2022-12-31","value":-19292800000,"profit":false},{"date":"2023-12-31","value":-7420400000,"profit":false}] |
Income Taxes | (1.92M) | (1.08M) | (4.42M) | (2.83M) | 452.00K | [{"date":"2019-12-31","value":-423.67,"profit":false},{"date":"2020-12-31","value":-239.16,"profit":false},{"date":"2021-12-31","value":-978.54,"profit":false},{"date":"2022-12-31","value":-626.11,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (64.79M) | (53.02M) | (59.24M) | (190.10M) | (74.66M) | [{"date":"2019-12-31","value":-6479000000,"profit":false},{"date":"2020-12-31","value":-5302000000,"profit":false},{"date":"2021-12-31","value":-5923700000,"profit":false},{"date":"2022-12-31","value":-19009800000,"profit":false},{"date":"2023-12-31","value":-7465600000,"profit":false}] |
Income From Continuous Operations | (64.79M) | (53.02M) | (59.24M) | (190.10M) | (75.72M) | [{"date":"2019-12-31","value":-6479000000,"profit":false},{"date":"2020-12-31","value":-5302000000,"profit":false},{"date":"2021-12-31","value":-5923700000,"profit":false},{"date":"2022-12-31","value":-19009800000,"profit":false},{"date":"2023-12-31","value":-7572500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (64.79M) | (53.02M) | (59.24M) | (190.10M) | (74.66M) | [{"date":"2019-12-31","value":-6479000000,"profit":false},{"date":"2020-12-31","value":-5302000000,"profit":false},{"date":"2021-12-31","value":-5923700000,"profit":false},{"date":"2022-12-31","value":-19009800000,"profit":false},{"date":"2023-12-31","value":-7465600000,"profit":false}] |
EPS (Diluted) | (0.85) | (0.73) | (0.78) | (2.44) | (0.85) | [{"date":"2019-12-31","value":-85,"profit":false},{"date":"2020-12-31","value":-73,"profit":false},{"date":"2021-12-31","value":-78,"profit":false},{"date":"2022-12-31","value":-244,"profit":false},{"date":"2023-12-31","value":-85,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
LAB | |
---|---|
Cash Ratio | 3.04 |
Current Ratio | 3.76 |
Quick Ratio | 3.41 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
LAB | |
---|---|
ROA (LTM) | -14.69% |
ROE (LTM) | -37.25% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
LAB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.28 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.72 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
LAB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5.28 |
P/B | 1.68 |
Price/FCF | NM |
EV/R | 3.50 |
EV/Ebitda | NM |
Standard Biotools Inc (LAB) share price today is $1.985
Yes, Indians can buy shares of Standard Biotools Inc (LAB) on Vested. To buy Standard Biotools Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Standard Biotools Inc (LAB) via the Vested app. You can start investing in Standard Biotools Inc (LAB) with a minimum investment of $1.
You can invest in shares of Standard Biotools Inc (LAB) via Vested in three simple steps:
The 52-week high price of Standard Biotools Inc (LAB) is $3.04. The 52-week low price of Standard Biotools Inc (LAB) is $1.21.
The price-to-earnings (P/E) ratio of Standard Biotools Inc (LAB) is
The price-to-book (P/B) ratio of Standard Biotools Inc (LAB) is 1.68
The dividend yield of Standard Biotools Inc (LAB) is 0.00%
The market capitalization of Standard Biotools Inc (LAB) is $796.63M
The stock symbol (or ticker) of Standard Biotools Inc is LAB